Subtype
Hepatocellular Carcinoma
CI-CAN-00002853HCC · LIHCExplore in graph →
693 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002853HCC · LIHCExplore in graph →
Clinical trials
3,126 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (357)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01539018 | Sorafenib Plus Tegafur-uracil (UFT) Versus Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation and/or TACE | terminated | Phase 2 | 77 | Egyptian Society of Liver CancerOTHER | 1 | Aug 5, 2015 | clinicaltrials |
| NCT01686880 | Y90 Radioembolization Prior to Surgical Resection or Radiofrequency for Hepatocellular Carcinoma in Cirrhotic Liver(TRYPHON) | terminated | Phase 2 | 10 | Jules Bordet InstituteOTHER |
| 1 |
| Jul 1, 2015 |
| clinicaltrials |
| NCT01029418 | AZD6244 and Sorafenib in Advanced Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 30 | National Cancer Centre, SingaporeOTHER | 1 | Apr 16, 2015 | clinicaltrials |
| NCT00081900 | A Safety and Efficacy Study of DENSPM in Patients With Liver Cancer Who Are Not Eligible for Surgical Care | terminated | Phase 1 / Phase 2 | 38 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Apr 13, 2015 | clinicaltrials |
| NCT00023946 | BMS-247550 in Treating Patients With Liver or Gallbladder Cancer | terminated | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT01215565 | Study of Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Carcinoma(Fibrolam) | terminated | Phase 2 | 4 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Mar 13, 2014 | clinicaltrials |
| NCT01128803 | Immunotherapy of Hepatocellular Carcinoma by Induction of Anti-alpha Fetoprotein Response | terminated | Phase 1 / Phase 2 | 1 | Nantes University HospitalOTHER | 1 | Nov 7, 2013 | clinicaltrials |
| NCT00862082 | Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 14 | Proacta, IncorporatedINDUSTRY | 4 | Aug 23, 2013 | clinicaltrials |
| NCT00405873 | Study to Evaluate Tumour Response in Cancer Patients With Advanced Hepatocellular Carcinoma (Liver Cancer) With AMT2003 | terminated | Phase 2 | 73 | Auron Healthcare GmbHINDUSTRY | 1 | Mar 20, 2013 | clinicaltrials |
| NCT00047333 | Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed | terminated | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00966251 | Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 2 | CureTech LtdINDUSTRY | 1 | Oct 23, 2012 | clinicaltrials |
| NCT00618384 | TACE and Sorafenib for Advanced Hepatocellular Carcinoma (HCC)(SOCRATES) | terminated | Phase 2 | 43 | Heinrich-Heine University, DuesseldorfOTHER | 1 | Jun 7, 2012 | clinicaltrials |
| NCT00151671 | Effect of a Perioperative Oral Nutritional Supplementation on Patients Undergoing Hepatic Surgery for Liver Cancer(IMPACT) | terminated | Phase 2 / Phase 3 | 35 | Rennes University HospitalOTHER | 1 | Feb 27, 2012 | clinicaltrials |
| NCT00280007 | Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | terminated | Phase 2 | 32 | Medical University of ViennaOTHER | 1 | Apr 22, 2010 | clinicaltrials |
| NCT00319683 | A Study of ADH300004 and 5-Fluorouracil in Locally Advanced, Recurrent, or Metastatic Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | — | Adherex Technologies, Inc.INDUSTRY | 3 | Dec 15, 2008 | clinicaltrials |
| NCT00165633 | A Phase II/III Clinical Study on Inhibitory Effects of E0167 on Recurrence of Hepatocellular Carcinoma | terminated | Phase 2 / Phase 3 | 540 | Eisai LimitedINDUSTRY | 1 | Dec 9, 2008 | clinicaltrials |
| NCT00351195 | Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC) | terminated | Phase 2 | 39 | Rigshospitalet, DenmarkOTHER | 1 | Aug 26, 2008 | clinicaltrials |
| NCT00440934 | A Study of Electromagnetic Waves in the Treatment of the Advanced Hepatocarcinoma(THBC002) | terminated | Phase 2 | 0 | Pasche, Boris, M.D.INDIV | 1 | May 6, 2008 | clinicaltrials |
| NCT00034333 | Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads Vs. IV Doxorubicin in Treating Liver Cancer | terminated | Phase 2 / Phase 3 | 240 | FeRxINDUSTRY | 8 | Jun 24, 2005 | clinicaltrials |
| NCT00057382 | T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients | terminated | Phase 2 / Phase 3 | 750 | TularikINDUSTRY | 11 | Jun 24, 2005 | clinicaltrials |
Data updated 23 days agoSource updated Aug 5, 2015source: clinicaltrials